Clinical Trials Logo

JMML clinical trials

View clinical trials related to JMML.

Filter by:
  • None
  • Page 1

NCT ID: NCT05849662 Not yet recruiting - Neurofibromatosis 1 Clinical Trials

A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia

Start date: November 30, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This clinical trial will test the safety and efficacy of combining trametinib and azacitidine in patients with juvenile myelomonocytic leukemia (JMML). Newly diagnosed lower-risk JMML patients will receive trametinib and azacitidine. High-risk JMML patients will receive trametinib, azacitidine, fludarabine, and cytarabine.

NCT ID: NCT04505995 Recruiting - JMML Clinical Trials

Azacitidine and Homoharringtonine in JMML

Start date: January 1, 2020
Phase: N/A
Study type: Interventional

Juvenile myelomonocytic leukemia (JMML) has a poor prognosis in general, with hematopoietic stem cell transplant (HSCT) remaining the standard of care for cure. Azacitidine and homoharringtonine, which exhibited a anticancer mechanism and has been widely used in patients with relapse/refractory acute myeloid leukemia (AML). However, the efficacy of these agents has not been elucidated in children with JMML. The primary objective is to assess the treatment effect on response rate in this subject population.

NCT ID: NCT00176930 Terminated - Multiple Myeloma Clinical Trials

Stem Cell Transplant for Hematological Malignancy

Start date: October 2001
Phase: N/A
Study type: Interventional

The purpose of this study is to develop a standard of care treatment using allogeneic stem cells for patients with cancers of the blood. The protocol was revised to reflect that this study is considered "treatment guidelines", rather than a research study.